For example, Dinaciclib [201] is a multi-CDK inhibitor that does not act against CDK4/6, and it has shown efficacy in pancreatic cancer in vitro and in vivo mouse model systems [202]. Here, CDK4 is linked to familial pancreatic carcinoma.